期刊文献+

LC-MS法测定人血浆匹伐他汀药物浓度及应用 被引量:3

LC-MS Determination of Pitavastatin in Human Plasma and Its Application
原文传递
导出
摘要 目的建立液质联用(LC-MS)直接沉淀法测定人血浆匹伐他汀的浓度。方法 Waters Cosmosil Packed Coulmn C18-MS-Ⅱ(2.0mm×150mm,5μm)色谱柱,流动相为10mmol·L-1甲酸胺(含0.1%甲酸)-乙腈(40∶60),流速为0.3mL·min-1,进样体积为20μL,柱温为40℃,样品室温度为15℃,采用内标定量法,内标为罗素伐他汀。结果匹伐他汀线性范围为0.5~1000 ng·mL-1,最低检测限为0.1ng·mL-1,方法灵敏、稳定、特异性高,并已成功地应用到人血浆匹伐他汀药动学研究。结论该方法简便、准确、重复性好,可以准确地定量人血浆匹伐他汀的浓度,适于药理科研。 OBJECTIVE To develop a LC-MS method with direct precipitation of sample protein to determinate the concentration of pitavastatin in human plasma.METHODS LC-MS equipment with ESI source and Waters Cosmosil Packed Coulmn C18-MS-Ⅱ(2.0 mm×150 mm,5 μm) were used in the experiment.The column temperature was set at 40 ℃.10 mmol·L-1 ammonium formate(contain 0.1% formic acid)-acetonitrile(40∶60) was used as mobile phase and the flow rate was 0.3 mL·min-1.The sample room temperature was set at 15 ℃ and the injection volume was 20 μL.Rosuvastatin was taken as the internal standard.RESULTS Pitavastatin was linear in the range of 0.5-1 000 ng·mL-1.The limitation of detection for pitavastatin was 0.1 ng·mL-1.The method was sensitivity,stability and specificity and was used for pharmacokinetic study of pitavastatin in human successfully.CONCLUSION The method is simple,accurate,reproducibility for the determination of pitavastatin in human plasma and suitable for the study in pharmacology.
出处 《中国药学杂志》 CAS CSCD 北大核心 2011年第2期134-137,共4页 Chinese Pharmaceutical Journal
关键词 匹伐他汀 液质联用 直接沉淀 pitavastatin LC-MS precipitation
  • 相关文献

参考文献7

二级参考文献62

  • 1Mukhtar RY, Reid J, Reckless JP. Pitavastatin[ J]. Int J Clin Pract, 2005 ;59:239 -252.
  • 2Reinoso RF, S Navarro A ,Garcia MJ, et al. Preclinical pharmacokinetics of statins [ J ]. Methods Find Exp Clin Pharmacol, 2002 ; 24 : 593 -613.
  • 3Garcia MJ, Reinoso RF, Navarro AS,et al. Clinical pharmacokinetics of statins [ J ]. Methods Find Exp Clin Pharmacol, 2003 ; 25 : 457 - 481.
  • 4Fujino H, Kojina J, Yamada Y ,et al. Studies on the metabolic fate of NK- 104, a new inhibitor of HMG- CoA reductase (4) : Interspecies variation in laboratory animals and humans[ J]. Xenobiol Metab Dispos, 1999; 14:79-81.
  • 5Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: Implications for therapeutic selection [ J ]. Am J Med,2001 ; 111 : 390 -400.
  • 6Wierzbicki AS, Poston R, Ferru A. The lipid and nonlipid effects of statins[ J]. Pharmacol Ther,2003 ; 99 : 95 - 112.
  • 7Fujino H, Yamada I, Kojima J ,et al. Studies on the metabolic fate of NK - 104, a new inhibitor HMG - CoA reductase (5) :In vitro metabolism and plasma protein binding in animals and human [ J ]. Xeno Metab Disp, 1999 ; 14:415 - 424.
  • 8Kimata H, Fujino H, Koide T,et al. Studies on the metabolic fate of NK - 104, a new inhibitor of HMG - CoA reductase ( 1 ) :Absorption, distribution, metabolism and excretion in rats [ J ]. Xenobiol Metab Dispos,1998; 13 : 484 -498.
  • 9Fujino H, Morikawa S, Kanda H,et al. Studies on the metabolic fate of NK - 104, a new inhibitor of HMG - CoA reductase (3) : Foeto - pla-cental transfer and mammary excretion after oral administration in rats [J] . Xenobiol Metab Dispos, 1998;13 : 508 -515.
  • 10Masaru H, Kazuya M, Yoshihisa S, et al. Contribution of OATP2 ( OATP1 B1 ) and OATP8 ( OATP1 B3 ) tothe hepatic uptake of pitavastatin in humans[J]. J Pharmacol Exp,2004 ;311 : 139 - 146.

共引文献55

同被引文献22

  • 1Kajinami K, Takekoshi N, Saito Y. Pitavastatin : efficacy and safety profiles of a novel synthetic HMG-GoA reductase inhibitor[ J]. Card- iovasc Drug Rev, 2003,21 ( 3 ) :199-215.
  • 2Bolego C, Poli A, Cignarella A, et al. Novel statins: pharmacologi- cal and clinical results [ J ]. Cardiovasc Drug Ther,2002,16 ( 3 ) : 251 -257.
  • 3Fujino H, Nakai D, Nakagomi R, et al. Metabolic stability and up- take by human hepatocytes of pitavastatin, a new inhibitor of HMG- CoA reductase [ J ]. Arzneimittelforschung ,2004 ,54 (7) :382-388.
  • 4Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alter- ations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc- tase inhibitorsl drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions [ J ]. Pharmacol Ther, 2006,112 ( 1 ) :71-105.
  • 5Di B, Su MX, Yu F, et al. Solid-phase extraction and liquid chro- matography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clin- ical pharmacokinetic studies [ J ]. J Chromatogr B Analyt Teehnol Bi- omed Life Sci,2008,868(1-2) :95-101.
  • 6Lv H, Sun JG, Wang GJ, et al. Determination of pitavastatin in hu- man plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers [ J ]. Clin Chim Acta, 2007,386(1-2) :25-30.
  • 7KOSTER A, SPIESS B, JURMANN M, et ol. Bivalimdin provides rapid, effective,and reliable anticoagulation during Off- Pmnp coro- nary revascularization : results of tne" EVOLUTION OFF" trial [ J ]. Anesth Analg , 2006,103(3) :540-544.
  • 8NICHOLAS G, SMEDIRA, CORNELIUS M D. Antieoagulation with bivalirudin for off - pump coronary artery bypass grafting : The results of the EVOLUTION - OFF study [ J ]. J Thorac Cardiov Sur, 2006,131 (3) :686-692.
  • 9FARTHING D,LARUS T,FAKHRY I. Liquid chromatography method for determination of bivalirudin in human plasma and urine using au- tomatedortho-phthalaldehyde derivatization and fluorescence detection [ J ]. J Chromatography B,2004,802:355-359.
  • 10PAN G X,WANG X M,HUANG Y H,et al. Development and val- idation of a LC-MS/MS method for determination of bivalirudin in human plasma: Application to a clinical pharmacokinetic study [ J]. J Pharm Biomed Analy, 2010,52 : 105-109.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部